- The US FDA has granted permission for Atossa Therapeutics ( NASDAQ: ATOS ) to start a phase 2 trial for ( Z )-endoxifen in ER+ and HER2- breast cancer.
- The phase 2 study is designed to examine ( Z )-endoxifen as a neoadjuvant treatment of premenopausal women ages 18 and older with Grade 1 or 2 ER+/HER2- breast cancer.
- Atossa also said that it is discontinuing its COVID-19 program, AT-301, to focus resources on ( Z )-endoxifen.
- See why Seeking Alpha contributor Bret Jensen gives Atossa ( ATOS ) an "incomplete rating."
For further details see:
Atossa receives FDA OK to begin phase 2 trial of (Z)-endoxifen for breast cancer